Cullinan Therapeutics posted Q2 2026 results alongside a pipeline update, highlighting continued progress in its T cell engager programs. Its CLN-049 candidate

Cullinan Therapeutics posted Q2 2026 results alongside a pipeline update, highlighting continued progress in its T cell engager programs. Its CLN-049 candidate has advanced to Phase 2 in relapsed/refractory AML after positive FDA feedback; more milestones are ahead.